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Physician participation in initiatives approved by the American Board of Medical Specialties (ABMS)
Multi-Specialty Portfolio Program can earn them 25 Improvement in Medical Practice (IMP/Part IV)
credit from their ABMS Member Board for maintenance of certification (MOC) and 20 Category 1
Performance Improvement-Continuing Medical Education (PI-CME) credits for physician assistants
through the National Commission on Certification of Physician Assistants (NCCPA).
As an approved portfolio sponsor, Envision NM 2.0 has been approved by the ABMS Multi-Specialty
Portfolio Approval Program Organization to approve QI Activities for MOC (IMP/Part IV) for physicians
and Category 1 PI-CME credit for physician assistants
ONLY American Board of Pediatrics (ABP) Residents can “bank” Maintenance of Certification (MOC)
(IMP/Part IV) credit that will be applied towards the MOC requirements once board certification is
achieved. Pediatric residents are able to earn MOC credit for approved quality improvement projects that
are completed during residency. Once the resident passes the (ABP) examination, they will be enrolled in
MOC and the “banked MOC Part (IMP/IV credit)” will count!
Participating physicians, physician assistants and other health care team members can also earn 25 CME
Credits from UNM Health Science School Of Medicine Office Of Continuing Medical Education.

Associations between maternal iron-deficiency anemia and neonatal outcomes in New Mexico
In Progress Research
Brandi Bahringer, MD
Background: Iron deficiency anemia (IDA) in pregnant women is associated with adverse neonatal
outcomes such as premature labor, low birth weight and adverse neurodevelopmental outcomes.
Neonates born to mothers not identified as having IDA and without treatment may be at higher risk
than those with mothers that receive treatment. In New Mexico, there is currently no data to evaluate
this.
Objective: Evaluate the effect of maternal IDA on neonatal outcomes including birth weight, length of
stay, gestational age and mortality. We hypothesized infants born to mothers with IDA are likely to have
associated morbidity and mortality.
Methods: Retrospective chart review of infants identified as being born to mothers with possible IDA
who were admitted to the NICU over 1 year was performed. Maternal charts were also reviewed. Chisquared test or Fisher exact test used for categorical variables. Wilcoxon Rank Sum test used for median
comparison. Risk of adverse outcome was adjusted for prematurity.
Results: 182 neonatal-maternal dyad charts were reviewed, 33 were excluded for major anomalies or
multiple gestation. 69 mothers were identified having IDA. 63 were screened for IDA (98%). Only 52
mothers were treated for IDA (48%). No statistically significant difference was identified between IDA
and non-IDA groups regarding gestational age, birth weight or length of stay.
Conclusions: In this study there was no statistically significant associated morbidity or mortality of
neonates born to mothers with IDA in the state of New Mexico. The study did identify gaps in maternal
medical care such as obtaining iron studies and treating for IDA. As IDA is easily identifiable and
treatable, additional research into gaps in maternal medical care and potential interventions would be
beneficial to the maternal-infant dyad.

Antibiotic use for children in the PICU with severe viral bronchiolitis
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BACKGROUND: Viral bronchiolitis is not treated with antibiotics, but with supportive care. Antibiotics
may be used for secondary bacterial pneumonia, which is difficult to diagnose in small children.
Children with severe bronchiolitis are admitted to the PICU, and often receive empiric antibiotics.
OBJECTIVES: To examine clinical factors associated with systemic antibiotic use in severe bronchiolitis
based on retrospective chart review of PICU patients.
METHODS: We identified children discharged from the UNMH PICU from January 2017-January 2019
diagnosed with severe viral bronchiolitis. Variables extracted included demographics, treatments, lab
values and outcomes. Stata/SE 15.1 was used to calculate descriptive statistics and to examine
relationships between clinical factors and antibiotic administration using a t-test, Pearson’s chi-square
test or Fisher’s exact test.
RESULTS: Children (n=208) were on average 11.3 ± 8.6 (SD) months old with a length of stay of 10.8 ±
6.4 days. Seventy children (34%) received antibiotics. Fifteen children (7%) had a definitive diagnosis of
bacterial pneumonia (positive tracheal culture). Children who received antibiotics were slightly younger
than those who did not (average age 10.3 vs. 11.9 months; p = 0.09). Fifty-four percent of children on a
ventilator (n=26) received antibiotics versus 31% of children who were not ventilated (p=0.02). Fortyone percent of children with elevated temperature (≥38°C; n=115) received antibiotics versus 24% of
children with normal temperature (n=89; p=0.009). Seventy-two percent of children with high CRP (>2
mg/L; n=18) received antibiotics versus 56% of children with normal CRP (n=18; p=0.24).
CONCLUSIONS: In the UNMH PICU, a substantial proportion of children with severe viral bronchiolitis
receive antibiotics without a definitive diagnosis of bacterial pneumonia. These children were younger
and sicker, with fever, elevated CRP and mechanical ventilation. An evidence-based, expert opinion
supported, clinical decision-making algorithm is needed to better identify children that require systemic
antibiotics in the setting of severe viral bronchiolitis.

